Cantor Fitzgerald raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $29 from $23 and keeps an Overweight rating on the shares. The FDA has granted Phathom Pharmaceuticals 10-year exclusivity for Voquenza, which extends the exclusivity period to May 2032 instead of 2030, adding about $6 per share to the firm’s distributable cash flow estimates, the analyst tells investors in a research note. Cantor says the overhang has been removed and continues to view Voquenza as a “great” drug in the acid-suppression space with more room to grow.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Stifel expects Phathom to ‘largely recover ground lost’ after FDA grants claim
- Phathom says FDA to correct Orange Book for Voquenza exclusivity
- Phathom jumps 124% to $10.49 after FDA corrects Voquenza exclusivity
- Largest borrow rate increases among liquid names
- Biotech Alert: Searches spiking for these stocks today